Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
NCT ID NCT03069703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy. The goal was to see if these 'reinforced' strategies are more effective and safe than the usual one-dose approach. The trial has completed, and results will show if the stronger schedules lead to better antibody responses against 12 pneumococcal serotypes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pneumococcal vaccines (PCV13 and PPV23) and rituximab
- What this could lead to
- If successful, this could lead to better protection against pneumococcal infections for people with ANCA vasculitis who are on rituximab therapy.
- What could go wrong
- This is a small Phase 2 trial with only 96 participants, so results may not apply to everyone. The vaccines may not produce a strong immune response in these patients, and there is a risk of side effects like injection site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pôle de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques " Hôpital Cochin, Assistance Publique-Hôpitaux de Paris
Paris, Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Can a new drug tame vasculitis with fewer side effects?
- Engineered immune cells take aim at autoimmune kidney diseases
- Could a diabetes drug shield kidneys from autoimmune attack?
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- New tool could predict who will suffer from steroid side effects